CD20 overexpression
|
Diffuse Large B Cell Lymphoma
|
CD20 overexpression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: C3 – Early Trials
|
R-CHOP Sensitive: C3 – Early Trials
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CVAD Resistant: C4 – Case Studies
|
CVAD Resistant: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CEOP-E Resistant: C4 – Case Studies
|
CEOP-E Resistant: C4 – Case Studies
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
CD20 overexpression
|
Peripheral T-cell Lymphoma
|
DICE Resistant: C4 – Case Studies
|
DICE Resistant: C4 – Case Studies
|